Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

BPTS

Biophytis ADR

Apr 24 • 04:00PM ET

9.70

Dollar change -0.49
Percentage change -4.78	%

Healthcare • Biotechnology • France • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-140.95	Insider Own	-	Shs Outstand	0.26M	Perf Week	-16.47%
Market Cap	3.40M	Forward P/E	-	EPS next Y	-2.02	Insider Trans	-	Shs Float	-	Perf Month	-35.45%
Income	-18.41M	PEG	-	EPS next Q	-	Inst Own	1.46%	Short Float	-	Perf Quarter	-51.50%
Sales	0.00M	P/S	-	EPS this Y	-100.00%	Inst Trans	-62.93%	Short Ratio	1.04	Perf Half Y	-73.49%
Book/sh	-16.48	P/B	-	EPS next Y	0.00%	ROA	-100.56%	Short Interest	0.01M	Perf Year	-93.65%
Cash/sh	17.57	P/C	0.55	EPS next 5Y	-	ROE	-	52W Range	8.47 - 168.80	Perf YTD	-63.83%
Dividend Est.	-	P/FCF	-	EPS past 5Y	51.26%	ROI	-	52W High	-94.25%	Beta	1.11
Dividend TTM	-	Quick Ratio	0.72	Sales past 5Y	0.00%	Gross Margin	-	52W Low	14.56%	ATR (14)	2.20
Dividend Ex-Date	-	Current Ratio	0.72	EPS Y/Y TTM	76.02%	Oper. Margin	0.00%	RSI (14)	34.74	Volatility	19.30% 15.67%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	4.04
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.42	Prev Close	10.19
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	8.91K	Price	9.70
SMA20	-26.48%	SMA50	-41.67%	SMA200	-73.18%	Trades		Volume	5,706	Change	-4.78%

Apr-24-24 05:30PM	Biophytis Announces Transfer of ADSs to OTC Market (ACCESSWIRE)
Apr-19-24 01:20AM	Biophytis Announces Ratio Change Under its American Depositary Receipt ("ADR") Program (ACCESSWIRE) -11.01%
Apr-18-24 01:20AM	Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity (ACCESSWIRE) +12.26%
Apr-09-24 08:00AM	Why Is Biophytis (BPTS) Stock Up 43% Today? (InvestorPlace) +30.40%
07:02AM	Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up (Zacks)
06:10PM	Loading…
Apr-08-24 06:10PM	Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities (ACCESSWIRE) -6.95%
05:30PM	Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) (ACCESSWIRE)
Apr-04-24 05:20PM	Results of the Combined General Meeting on April 2, 2024 (ACCESSWIRE)
Mar-22-24 02:20AM	Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia (ACCESSWIRE)
Nov-17-23 05:15PM	Biophytis Announces Receipt of Nasdaq Notice (ACCESSWIRE)
Oct-30-23 01:20AM	Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in Brazil (ACCESSWIRE) +10.99%
Oct-27-23 05:15PM	Biophytis Receives Notice of Delisting From NASDAQ and Announces It Will Request a Hearing Before the NASDAQ Hearings Panel (ACCESSWIRE)
Sep-27-23 05:45PM	Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its Operations (ACCESSWIRE) +7.35%
Sep-25-23 12:09PM	Biophytis shares surge 73% following partnership deal with Skyepharma (Investing.com) +80.66%
01:30AM	Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101) (ACCESSWIRE)
01:40AM	Loading…
Sep-19-23 01:40AM	Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19 (ACCESSWIRE) -13.14%
Sep-14-23 01:30AM	Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer (ACCESSWIRE)
Sep-11-23 01:20AM	Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia (ACCESSWIRE)
Sep-04-23 05:30PM	Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York (ACCESSWIRE)
Aug-16-23 01:15AM	Biophytis Announces Next Regulatory Steps in Europe and the United States for its COVA Project (ACCESSWIRE) +5.15%
Aug-08-23 01:20AM	Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe (ACCESSWIRE)
Jul-20-23 01:20AM	Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19 (ACCESSWIRE) -16.21%
Jul-19-23 02:20AM	Biophytis Announces $3.8 Million Registered Direct Offering (ACCESSWIRE) -12.86%
Jul-18-23 01:20AM	Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound (ACCESSWIRE) +40.72%
Jul-10-23 01:00AM	Biophytis Has Filed with The FDA For Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia (ACCESSWIRE)
Jun-19-23 01:30AM	Biophytis Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress (ACCESSWIRE)
Jun-16-23 05:20PM	Biophytis: Results of the Annual General Meeting on June 16, 2023 All Resolutions Presented by the Company Have Been Adopted (ACCESSWIRE)
Jun-05-23 02:20AM	Biophytis to Participate at the BIO International Convention in Boston from the 5th to the 8th of June (ACCESSWIRE)
May-26-23 02:30AM	Biophytis has Filed with the French National Authority for Health (HAS) an Application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19 (ACCESSWIRE)
May-25-23 02:20AM	Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference (ACCESSWIRE)
02:20AM	Loading…
May-15-23 02:20AM	Biophytis has Filed with the EMA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia (ACCESSWIRE)
May-11-23 02:20AM	Successful Capital Increase for Biophytis with 2.3 million Raised (ACCESSWIRE) -22.46%
May-10-23 02:10PM	Biophytis Launches a Round of Fundraising for Approximately 2 Million Euros (ACCESSWIRE)
May-09-23 02:20AM	Biophytis has Requested a Pre-Submission Meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the Treatment of COVID-19 (ACCESSWIRE)
May-02-23 02:20AM	Biophytis Strengthens its Management Team (ACCESSWIRE) -11.04%
Apr-28-23 05:30PM	Biophytis Announces Receipt of Nasdaq Notice (ACCESSWIRE) +13.24%
Apr-19-23 02:20AM	Biophytis Regains Compliance with NASDAQ Minimum Bid Price Requirement (ACCESSWIRE) +12.60%
Apr-18-23 03:45AM	Biophytis Announces 2022 Financial Results and 2023 Perspectives (ACCESSWIRE)
12:20AM	Biophytis: Results of the Combined General Meeting on April 17, 2023 (ACCESSWIRE)
Mar-30-23 05:20PM	Biophytis: The Combined General Meeting Will Be Held on Second Call on April 17, 2023 (ACCESSWIRE) +21.41%
Mar-27-23 02:20AM	Biophytis: Biophytis Presented Sarconeos (BIO101) As A Possible Treatment Candidate for Long COVID After Hospitalization During The 13th Annual International Conference on Frailty and Sarcopenia Resea (ACCESSWIRE)
Mar-17-23 03:20AM	Biophytis Announces Ratio Change Under its American Depositary Receipt (ADR) Program (ACCESSWIRE) -13.05%
Mar-09-23 02:20AM	Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference (ACCESSWIRE) +18.10%
Mar-02-23 02:00AM	Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19 (ACCESSWIRE) +41.09%
Feb-27-23 02:20AM	Biophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19 (ACCESSWIRE)
Feb-23-23 02:20AM	Biophytis To Host a Combined General Shareholders Meeting on March 30, 2023 (ACCESSWIRE) -5.25%
Feb-02-23 02:20AM	Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19 (ACCESSWIRE) +73.13%
Jan-31-23 02:20AM	Biophytis Publishes its Financial Results for the First Half of 2022 (ACCESSWIRE)
Jan-19-23 02:00AM	Biophytis: Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd (ACCESSWIRE)
Jan-12-23 02:20AM	Biophytis To Take Appropriate Measures After Receiving Nasdaq Deficiency Notice (ACCESSWIRE)
Jan-05-23 02:20AM	Biophytis Announces Its Participation in Two Major Investor Conferences in January, In the United States and In France: The JP Morgan Healthcare Conference and The Invest Securities Biomed (ACCESSWIRE) -6.44%
Dec-01-22 02:30AM	Biophytis Organises a Webcast with Key Opinion Leaders (KOL) On the Phase 2-3 Cova Study Results of Sarconeos (Bio101) In the Treatment of Pneumonia in Covid-19 Patients at Risk of Respiratory Failure (ACCESSWIRE) -25.81%
Nov-03-22 09:13AM	Biophytis Shares Gain After Detailed Data From Pivotal COVID-19 Treatment Study (Benzinga) -9.32%
03:20AM	Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19 (ACCESSWIRE)
Oct-31-22 07:10PM	Biophytis Publishes Its Key Financial Figures As at 30 June 2022, Announces a Restatement of the Financial Statements Published As of December 31st, 2021 and Provides an Update on the Operational Milestones (ACCESSWIRE)
Oct-26-22 02:45AM	Biophytis Announces Receipt of Nasdaq Notice (ACCESSWIRE) +6.37%
Sep-15-22 02:30AM	Biophytis Participates in H.C. Wainwright 24th Annual Global Investment Conference (ACCESSWIRE)
Sep-13-22 02:20AM	The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd (ACCESSWIRE) -5.92%
Sep-07-22 07:05AM	Biophytis Shares Surge After Promising Data From COVID-19 Treatment Study (Benzinga) +18.09%
02:20AM	Biophytis Announces Very Promising Top Line Results of its Phase 2-3 COVA Clinical Study in COVID-19-Related Respiratory Failure (ACCESSWIRE)
Jun-30-22 05:20PM	Biophytis Announces the Drawing of the Second Tranche of Ornane Under the 2021 Atlas Contract for 4 Million (ACCESSWIRE) -19.29%
Jun-27-22 05:45PM	Biophytis Presents the Development of Sarconeos (BIO101) in Phase 3 for the Treatment of Sarcopenia at the 15th SCWD International Congress (ACCESSWIRE) -9.26%
Jun-22-22 05:30PM	Biophytis: Results of the Combined General Meeting on June 21, 2022 (ACCESSWIRE)
Jun-03-22 05:20PM	Biophytis: Convening of Another Combined General Meeting at a Later Date (ACCESSWIRE) -11.63%
May-12-22 02:20AM	Biophytis: Biophytis Announces its Participation at the BIO International Convention in San Diego from the 13th to the 16th of June (ACCESSWIRE)
Apr-19-22 02:20AM	Biophytis: Biophytis Presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022 (ACCESSWIRE) -5.12%
Apr-07-22 08:11AM	Biophytis Shares Fall As It Stops Enrollment In Sarconeos COVID-19 Trial, Data Expected In Q3 2022 (Benzinga) -17.26%
02:25AM	Biophytis Provides Updates on Sarconeos (BIO101) Clinical Development (ACCESSWIRE)
02:25AM	Biophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives (ACCESSWIRE)
Apr-05-22 05:30PM	Biophytis Appoints Philippe Rousseau as Chief Financial Officer (ACCESSWIRE)
Mar-16-22 03:20AM	Biophytis will Participate in a Key Workshop on Functional Limitations for the Elderly (ACCESSWIRE)
Feb-03-22 09:03AM	Why Are Biophytis Shares Trading Higher During Premarket Trading? (Benzinga)
03:00AM	Biophytis Received Approval from ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients through an Expanded Access Program (ACCESSWIRE)
Dec-22-21 05:20PM	Biophytis Announces the Drawing of the Last Tranche of ORNANE Under the 2020 Atlas Contract for 3 Million (ACCESSWIRE)
Dec-16-21 02:30AM	Biophytis to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3 (ACCESSWIRE)
Nov-22-21 05:20PM	Biophytis Obtains a New 10M Loan Structure With Kreos Capital (ACCESSWIRE)
Nov-15-21 03:08PM	Biophytis To Restart Recruitment In US Centers For COVID-19 Trial (Benzinga) +5.37%
02:30AM	Biophytis Announces US Centers to Restart Recruitment for the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 (ACCESSWIRE)
Oct-29-21 02:55AM	Biophytis to Report Restated Financial Statements for Previous Periods and as of June 30, 2021 (ACCESSWIRE)
Oct-06-21 05:00PM	Biophytis to Restate Previously Issued Financial Statements (GlobeNewswire)
02:00AM	Biophytis to Host Virtual KOL Event on Sarconeos (BIO101) on its Lead Projects in COVID-19 and Sarcopenia (GlobeNewswire)
Oct-04-21 05:00PM	Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under the 2020 Atlas Contract for 6 Million (GlobeNewswire)
02:00AM	Biophytis Announces Promising Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 October 2, 2021 (GlobeNewswire)
Sep-29-21 02:00AM	Biophytis to Present Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 October 2, 2021 (GlobeNewswire) +15.01%
Sep-17-21 02:00AM	Biophytis Reports H1 2021 Financial Results and Provides Business Update (GlobeNewswire)
Sep-15-21 02:00AM	Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 COVA Study With Sarconeos (BIO101) in COVID-19 (GlobeNewswire)
Sep-14-21 02:00AM	Biophytis to Attend Key Upcoming Investor Events and Industry Conferences (GlobeNewswire)
Sep-09-21 02:00AM	Biophytis Leadership is Reinforced With New Chief Medical Officer Appointment (GlobeNewswire)
Aug-16-21 08:36AM	DMC Recommends Biophytis Continue Sarconeos COVID-19 Study (Benzinga)
02:00AM	Biophytis Receives Favorable Recommendation From Data Monitoring Committee (DMC) Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the COVA Study in COVID-19 (GlobeNewswire)
Aug-13-21 05:00PM	Biophytis Announces the Issue of 4,950,000 New Shares in a Capital Increase Reserved for NEGMA and the Performance of the Judgments of March 16, 2021 and July 16, 2021 (GlobeNewswire)
Aug-02-21 06:24AM	Biophytis Stock Gains As Sarconeos High Dose Improves Gait Speed Versus Placebo In Patients With Muscle Loss Due To Aging (Benzinga) +5.47%
02:00AM	Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia (GlobeNewswire)
Jul-19-21 05:00PM	Judgment Rendered on July 16, 2021 in the Proceedings Between Biophytis and Negma Group Ltd by the Execution Judge From the Paris Court of Justice (GlobeNewswire) -6.67%
Jul-12-21 12:53PM	Qiagen Stock Drops After Trimming FY21 Earnings Forecast On Weaker COVID-19 Testing Trends (Benzinga) +17.26%
11:10AM	Biophytis Stock Is Trading Higher On Encouraging Preclinical Data From COVID-19 Study With Sarconeos (Benzinga)
02:00AM	Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021 (GlobeNewswire)
Jul-08-21 02:00AM	Biophytis Reinforces Leadership Teams with Three Senior Appointments (GlobeNewswire)
Jun-30-21 05:00PM	Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021 (GlobeNewswire)
05:00PM	Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study (GlobeNewswire)

Biophytis SA operates as a clinical-stage biotechnology company. It specializes in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and Rene Lafont on September 27, 2006 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BPTS

Biophytis ADR

Upgrade your FINVIZ experience